Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Study: HBV infection reduces risk of liver metastasis in CRC patients

Colorectal cancer is the second leading cause of cancer-related deaths in Western countries. Metastatic liver disease more frequently develops metachronous metastasis following treatment of CRC.

9 Mar 2011

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

New Phase II data on multiple Bristol-Myers Squibb Company investigational hepatitis C compounds will be presented at The International Liver Congress, the 46th annual meeting of the European Association for the Study of the Liver in Berlin, Germany, from March 30 to April 2.

8 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs — despite the potential for abuse, addiction and overdose, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University.

4 Mar 2011

Hazardous high concentrations of cadmium found in inexpensive children's jewelry

Young children who mouth or swallow jewelry containing cadmium may be exposed to as much as 100 times the recommended maximum exposure limit for the toxic metal, according to research published online March 4 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP). The study measured bioavailability, or how much cadmium leached out of the jewelry. The research also found that damaged pieces of jewelry in some cases leached up to 30 times more cadmium than undamaged pieces.

4 Mar 2011

Wako i30 Immunoanalyzer incorporating Caliper's microfluidic LabChip technologies receives 510(k) clearance

Caliper Life Sciences, Inc. today announced that its licensee Wako Pure Chemical Industries, through its Wako Diagnostics division, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its uTASWako® i30 Immunoanalyzer and AFP-L3 and DCP Assays, which are used to assess liver cancer risk in patients with chronic liver disease.

4 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Scientists discover how change in growth hormone activity leads to fatty liver disease

Scientists at the UCSF Cardiovascular Research Institute have discovered how a change in growth hormone activity in mice leads to fatty liver disease, a condition whose human counterpart is of rising concern worldwide.

2 Mar 2011

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA.

2 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

Cryo-Cell fiscal 2010 net income increases to $3.4 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced results for its fiscal year 2010.

28 Feb 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

The Bristol-Myers Squibb Foundation has awarded four new grants to help improve awareness, prevention and care of hepatitis B and hepatitis C in China and India.

25 Feb 2011

Study: Low Vitamin D levels can cause allergies in children

A study of more than 3,000 children shows that low vitamin D levels are associated with increased likelihood that children will develop allergies, according to a paper published in the February 17 online edition of the Journal of Allergy and Clinical Immunology.

25 Feb 2011

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

New research has determined that patients in the U.S. with hepatitis C virus are twice as likely to not have health insurance coverage compared with those without the disease.

24 Feb 2011

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

24 Feb 2011

Nanoparticle therapy may improve survival after life-threatening blood loss

In an advance that could improve battlefield and trauma care, scientists at Albert Einstein College of Medicine of Yeshiva University have used tiny particles called nanoparticles to improve survival after life-threatening blood loss.

23 Feb 2011

Experimental vaccine appears to protect against pneumonia

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.

22 Feb 2011

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Liver Disease News and Research

Further Reading

Study: HBV infection reduces risk of liver metastasis in CRC patients

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs

Hazardous high concentrations of cadmium found in inexpensive children's jewelry

Wako i30 Immunoanalyzer incorporating Caliper's microfluidic LabChip technologies receives 510(k) clearance

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Scientists discover how change in growth hormone activity leads to fatty liver disease

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Cryo-Cell fiscal 2010 net income increases to $3.4 million

Scripps Health offers genetic testing to patients with Hepatitis C

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

Study: Low Vitamin D levels can cause allergies in children

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

Nanoparticle therapy may improve survival after life-threatening blood loss

Experimental vaccine appears to protect against pneumonia

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News